Unisense FertiliTech announces new partnership with William Demant Invest

Danish medtech company Unisense FertiliTech A/S announces a new partnership with Oticon Funds investment company William Demant Invest (WDI). WDI owns 32% of Unisense FertiliTech A/S after the purchase of new and existing shares in the company worth 24 million USD.

Unisense FertiliTech A/S develops and manufactures products to improve treatment in the field of assisted reproduction.  The company has expanded rapidly in the past 2 years, operating in more than 30 countries worldwide.  In addition to the current hardware and software product offerings, there is an exciting pipeline of products under development which hold significant commercial potential within the IVF industry.

With this new partnership and investment, the company will be in an excellent position to execute its long term development strategy and to accelerate the global expansion of sales of FertiliTech's existing and new products geared towards improving clinical practice in the field of IVF.

"We welcome WDI as an extremely knowledgeable, financially strong and experienced investor with a proven track record in the medtech field. We also look much forward to the benefits and synergies that can be achieved when applying extensive experience from the hearing aid industry to the area of assisted reproduction", says Unisense FertiliTech A/S CEO, Jens Gundersen.

William Demant Invest's CEO, Niels Jacobsen is very satisfied with the new investment and future goals: "We see excellent possibilities with FertiliTech.  It is a very professionally driven organization with a huge potential. In addition, their products and company profile are a good fit with our existing portfolio".

SOURCE Unisense FertiliTech A/S

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study suggests chain fertility clinics improve IVF outcomes